Accession #: HC16NY1-0000000

Gender: F Age: 46 Social Security Number: Patient ID/Case Number:



Date of Procedure: Date Received:

Clinical Information: Status: Relapse

Diagnosis under consideration: Follicular Cell

# **Hematology Comprehensive Summary Report**

**Final Diagnosis:** Mildly hypercellular marrow demonstrating trilineage hematopoiesis with maturation.

DOB: 00/0/0000

Features of involvement by a lymphoproliferative disorder are not seen.

A small lymphoid aggregate present, favor reactive.

Mild increase in stainable iron.

**Summary** 

**Morphology:** Bone marrow is slightly hypercellular. Erythroid elements are present in normal proportion.

Maturing myeloid elements are mildly increased and exhibit maturation. Megakaryocytes appear mildly increased. Immunoperoxidase studies reveal that the lymphoid aggregate and scattered small lymphocytes are approximately 5% showing mixed staining for CD3

and CD20.

Aspirate smears contain tiny spicules and are hypocellular. Scattered erythroid precursors show occasional dysplastic forms. Myeloid cells appear at various stages of development.

Scattered megakaryocytes appear adequate.

**Flow Cytometry:** No clonal B cells detected. T cells with unremarkable phenotype noted. No increase in

myeloblasts seen.

**FISH:** Negative for IGH/BCL2 Rearrangement.

Molecular Diagnostics: Not Ordered

**Cytogenetics:** Normal Female Karyotype: 46,XX[20]

Electronically signed out by:

Dr. Dongsheng Xu (877) 258-9310 9/7/2016

End of Report

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 1 of 1

Accession #: HC16NY1-0000000

Accession #: HM16NY1-0000000

Gender: F Age: 46
Social Security Number:
Patient ID/Case Number:



Date of Procedure:
Date Received:

Clinical Information: Status: Relapse

Diagnosis under consideration: Follicular Cell

# **Morphology Report**

DOB: 00/0/0000

Diagnosis: Mildly hypercellular marrow demonstrating trilineage hematopoiesis with maturation.

Features of involvement by a lymphoproliferative disorder are not seen.

A small lymphoid aggregate present, favor reactive.

Mild increase in stainable iron.

Submitted CBC Results: Date performed: 8/15/2016

WBC	Hgb	Hct	MCV	RDW	PLT
8.6	16.3	49	95	14.2	244
K/ul	g/dL	%	fL	%	K/ul

#### 1: Bone Marrow Core

#### Microscopic Description

Bone marrow biopsy is slightly hypercellular for the age (30-40% fat). Erythroid elements are present in normal proportion. Maturing myeloid elements are mildly increased and exhibit maturation. Megakaryocytes (highlighted by PAS stain) appear mildly increased.

Scattered plasma cells are <5%. One small lymphoid aggregate comprising small lymphocytes is noted. No granuloma or metastatic carcinoma is seen. Bone trabeculae are unremarkable. Iron stain reveals that stainable iron is increased. Reticulin stain reveals that reticulin appears normal.

Immunoperoxidase studies performed on paraffin-embedded sections reveal that the lymphoid aggregate and scattered small lymphocytes are approximately 5% showing mixed staining for CD3 and CD20 with more T cells over B cells.

#### **Gross Description**

Received in a white cap container with formalin, labeled with patient's name and "Bone Marrow" is one bone marrow core biopsy measuring 2.0 cm in length. The entire specimen is submitted in one cassette and labeled "1A".

# 2: Bone Marrow Clot

#### Microscopic Description

Bone marrow biopsy is slightly hypercellular for the age (30-40% fat). Erythroid elements are present in normal proportion. Maturing myeloid elements are mildly increased and exhibit maturation. Megakaryocytes (highlighted by PAS stain) appear mildly increased.

Scattered plasma cells are <5%. No granuloma, lymphoid aggregate or metastatic carcinoma is seen. Immunoperoxidase studies performed on paraffin-embedded sections reveal that scattered small lymphocytes are <5% showing mixed staining for CD3 and CD20.

## **Gross Description**

Received in a red cap container with formalin, labeled with patient's name and "Bone Marrow" is one clot measuring approximately 1.6 x 1.6 x 0.8 cm. The entire specimen is submitted in one cassette labeled "2A".

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave.,

Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient Page 1 of 2

Accession #: HM16NY1-000000

/it


# 3: Bone Marrow Cytology


# Microscopic Description


Description	
Cellularity	Aspirate smears contain tiny spicules and are hypocellular. Scattered erythroid precursors show occasional dysplastic forms. Myeloid cells appear at various stages of development. Scattered megakaryocytes appear adequate. Stainable iron appears adequate. No ring sideroblasts are noted.

### **Gross Description**

Received in plastic slide holders are 8 air-dried, unfixed and unstained bone marrow aspirate smears labeled with the patient's name,DOB "Bone Marrow". GD







**Core Biopsy** 

**Clot Section** 

**Aspirate Smear** 

#### Comments

Follicular Lymphoma- IGH/BCL2,t(14;18) (FISH) and Cytogenetics Work-up are pending. A comprehensive summary report will follow.

### **Electronically signed out by:**

Dr. Dongsheng Xu (877) 258-9310 9/2/2016

Images included in this report are for information only and are not intended for diagnosis.

Some tests performed at CBLPath Inc have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. In accordance to CLIA '88 requirements, this laboratory has verified the validity and accuracy of these tests for clinical purposes. CBLPath is regulated under the Clinical Improvement Amendments Acts of 1988 (CLIA) as qualified to perform high complexity testing.

End of Report

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573 Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 2 of 2

Accession #: HM16NY1-0000000

Gender: F Age: 46 Social Security Number: Patient ID/Case Number:

Date of Procedure: Date Received:

Clinical Information: Status: Relapse

Diagnosis under consideration: Follicular Cell

# **CBLPATH**

# **Flow Cytometry Report**

DOB: 00/0/0000

# Interpretation

No clonal B cells detected.

T cells with unremarkable phenotype noted.

No increase in myeloblasts seen.

## Findings

Flow cytometric analysis performed on bone marrow revealed that lymphocytes comprised approximately 19% of total cells analyzed.

There were 81% of CD2+, CD3+, CD5+, CD7+ T cells with a normal CD4/CD8 ratio, 7% of CD2+, CD16+, CD56+ NK cells and 4% of CD19+, CD20+, CD22+ polytypic B cells.


In addition, approximately 1% of CD33+, CD34+, CD117+ myeloblasts were also detected.

#### Comments

Specimen Type Bone Marrow Aspirate

**Body Site: Bone Marrow** 

Viability 99%



T-Cell Related			
CD Marker	%	Intensity	
CD5	78	Moderate	
CD8	29	Moderate	
CD2	88	Moderate	
CD4	54	Dim	
CD3	81	Dim	
CD7	75	Dim	

B-Cell Related		
CD Marker	%	Intensity
CD5/CD19	0	Negative
CD10/CD19	0	Negative
CD20	4	Dim
Карра	2	Moderate
CD22	3	Dim
CD19	4	Dim
Lambda	1	Moderate
CD23	0	Negative

Myeloid Related			
CD Marker	%	Intensity	
CD117	1	Negative	
CD33	5	Negative	
CD64	3	Negative	
CD14	3	Negative	
CD13	5	Negative	
CD16	11	Dim	

Miscellaneous		
CD Marker	%	Intensity
CD56	14	Dim
CD11b	23	Dim
CD45	99	Moderate
CD25	2	Negative
CD34	1	Negative
HLA-DR	26	Dim
CD10	0	Negative
CD38	19	Dim
CD138	0	Negative

#### Comments

Follicular Lymphoma- IGH/BCL2,t(14;18) (FISH) and Cytogenetics Work-up are pending. A comprehensive summary report will follow.

#### **Electronically signed out by:**

Dr. Dongsheng Xu

(877) 258-9310

8/30/2016

mages included in this report are for information only and are not intended for diagnosis.

Some tests performed at CBLPath Inc have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. In accordance to CLIA '88 equirements, this laboratory has verified the validity and accuracy of these tests for clinical purposes. CBLPath is regulated under the Clinical Improvement Amendments Acts of 1988 (CLIA) as qualified to perform high complexity testing.

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 1 of 1

Accession #: H16NY1-0000000

Sample, Patient A

Gender: F Age: 46 Atlantic Medical Imaging - Galloway

Social Security Number: Schmidling, Michael J MD

Patient ID/Case Number: Parkwood Professional Park 44 East

Jimmie Leeds Rd, Ste 101

DOB: 00/0/0000

Galloway, NJ 08205

Date of Procedure: Date Received: (609) 652-7349

Referring Physician: Stoyko, Zoryana

Phone: (609) 383 - 6033

Clinical Information: Status: Relapse

Diagnosis under consideration: Follicular Cell




Accession #: XF16NY1-0000000

# Fluorescence in situ Hybridization (FISH) Report\*

Interpretation: Negative for IGH/BCL2 Rearrangement.

TEST	Probe Results
Follicular Lymphoma- IGH/BCL2,t(14; 18) (FISH)	A disomic signal pattern for the IGH/BCL2 dual-fusion probe set was observed within normal cut-off limits. This represents a NEGATIVE result.
	ISCN: nuc ish(IGH,BCL2)x2 [200]



IGH/BCL2

Specimen Type/Site: Bone Marrow Aspirate, Bone Marrow

**Gross Description:** Received 6 ml BM in heparin green top, labeled with patient's name

and "Aspirate 2", submitted for Follicular Lymphoma-

IGH/BCL2,t(14;18) (FISH). /sa

Methodology: Fluorescence in situ hybridization analysis was performed on nuclei

derived from this Bone Marrow sample using the Follicular Lymphoma

- IGH/BCL2,t(14;18) (FISH) (manufactured by Vysis/Abbott

Molecular). A test is considered positive if the normal cut off value established at CBLPath, Inc. are exceeded in value. IGH/BCL2

(0.59% - 5.05%)

## Comments

Cytogenetics Work-up is pending. A comprehensive summary report will follow.

Case screened by: Cristina Steele, CG(ASCP)

Electronically signed out by:

Dr. Dongsheng Xu 9/2/2016

FISH analysis can only identify abnormalities that are within the specific locus of the probe(s) used and may not detect small clonal populations of aberrant cells below the normal cut-off values; therefore, FISH results should be interpreted in the context of the patient's full clinical history and under most circumstances, in conjunction with histomorphological and/or cytogenetic evaluation.

Images included in this report are for information only and are not intended for diagnosis.

Some tests performed at CBLPath Inc have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. In accordance to CLIA '88 requirements, this laboratory has verified the validity and accuracy of these tests for clinical purposes. CBLPath is regulated under the Clinical Improvement Amendments Acts of 1988 (CLIA) as qualified to perform high complexity testing.

End of Report

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 1 of 1

Accession #: XF16NY1-0000000

Gender: F Age: 46 Social Security Number: Patient ID/Case Number:




Date of Procedure: Date Received:

Clinical Information: Status: Relapse

Diagnosis under consideration: Follicular Cell

# **Cytogenetics Report**

DOB: 00/0/0000



Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 1 of 2

Accession #: XY16NY1-0000000

Sample, Patient A DOB: 00/0/0000 Accession #: XY16NY1-0000000

Specimen Type: Bone Marrow Aspirate

**Gross Description:** Received 8 ml BM in heparin green top, labeled with patient's name and "Aspirate 2", submitted

for Cytogenetics Work-up.\he

Methodology: Cytogenetic analysis was performed with two unstimulated cultures (24 and 48 hr). GTG banding

was performed on this case.

Comments: No chromosomal abnormalities were detected.

**Electronically signed out by:** 

Dr. Vundavalli Murty (877) 258-9310 9/6/2016

The karyotype test may not detect smaller deletions and cryptic rearrangements below the band-resolution of this procedure. A low frequency of karyotypic abnormalities may also be undetectable. A normal karyotype does not rule out cancer. Images included in this report are for information only and are not intended for diagnosis.

Some tests performed at CBL Path Inc have not been cleared or approved for specific uses by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. In accordance to CLIA '88 requirements, this laboratory has verified the validity and accuracy of these tests for clinical purposes. CBLPath is regulated under the Clinical Improvement Amendments Acts of 1988 (CLIA) as qualified to perform high complexity testing.

End of Report

Specimens processed and interpreted at CBLPath, Inc., 760 Westchester Ave., Rye Brook, NY 10573

Phone number: (877) 225-7284, NY License: 3954, CAP LAP# 7184143

Sample, Patient A

Page 2 of 2

Accession #: XY16NY1-0000000